Humana Beats Q3, Lifts 2026 Adjusted EPS Outlook to at Least $9.50
HUM has more than doubled off its 52-week low of $163.11.
Summary
Humana beat on the top and bottom line and raised full-year guidance, with CenterWell doing the heavy lifting. Revenue came in at $41.2B, about 26% higher year over year and $270M above consensus, as the health services segment added $7.2B versus the $6.76B analysts expected. The insurance side was messier: the benefit ratio rose 260 bps to 93.7%, worse than the 92.8% consensus, driven by the 2026 Star Ratings headwind and new Medicare Advantage members with higher utilization. Membership growth is the offset — 18.04M medical members, up 20% year over year and ahead of the 17.87M projected, with MA membership up roughly 24%. Management raised 2026 adjusted EPS guidance to at least $9.50 from at least $9.00, above the $9.16 consensus, and lifted GAAP EPS guidance to at least $15.09 from at least $6.52. This follows the October 9th disclosure that 95% of MA members sit in 4-star-plus plans for 2027, which underpins the margin recovery case Baird and RBC are pointing to.
At the time of this announcement, HUM was trading at $423.15 on NYSE in the Finance sector, with a market capitalization of approximately $50.8B. The 52-week trading range was $163.11 to $456.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.